0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Cancer Supportive Care Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: November 2024
|
Report Code: QYRE-Auto-22X5714
Home | Market Reports | Health| Health Conditions| Cancer
Global Cancer Supportive Care Drugs Market Insights and Forecast to 2028
BUY CHAPTERS

Cancer Supportive Care Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-22X5714
Report
November 2024
Pages:110
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Cancer Supportive Care Drugs - Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Cancer Supportive Care Drugs - Market

Cancer Supportive Care Drugs - Market

Cancer Supportive care also known as palliative care is focused on relieving patients from side effects of cancer therapies. In cancer palliative care, supportive drugs are used to lessen the side effects of cancer treatments. In many cases cancer treatments need to be stopped or doses need to lowered due various reasons such as low blood cell counts. In such cases, cancer supportive drugs such as CSFs enable patients to continue with cancer treatments as well as in other cases, it also allows higher doses of cancer therapies. Cancer being one of the leading causes of death worldwide, there has been increasing focus on cancer treatments. Many cancer treatments comes with various side effects such as fatigue, pain, fertility problems, depression, heartburn, sexual problems, bone diseases and other side effects. 
The global market for Cancer Supportive Care Drugs was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Cancer Supportive Care Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Cancer Supportive Care Drugs by region & country, by Type, and by Application.
The Cancer Supportive Care Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Supportive Care Drugs.
Market Segmentation

Scope of Cancer Supportive Care Drugs - Market Report

Report Metric Details
Report Name Cancer Supportive Care Drugs - Market
CAGR 5%
Segment by Type:
  • Granulocyte-Colony Stimulating Factors (G-CSFS)
  • Erythropoietin-Stimulating Agents (ESAS)
  • Antiemetics
  • Bisphosphonates
  • Opioids
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
  • Others
Segment by Application
  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Prostate Cancer
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Amgen, Johnson & Johnson, Novartis, Baxter International, Fagron Group, Teva Pharmaceuticals Industries, F.Hoffmann La-Roche Ltd, Apr Applied Pharma Science Research, Acacia Pharma, Kyowa Hakko Kirin, Helsinn Healthcare, Heron Pharma, Merck & Co. Inc, Sanofi
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Cancer Supportive Care Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Revenue of Cancer Supportive Care Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Revenue of Cancer Supportive Care Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Cancer Supportive Care Drugs - Market report?

Ans: The main players in the Cancer Supportive Care Drugs - Market are Amgen, Johnson & Johnson, Novartis, Baxter International, Fagron Group, Teva Pharmaceuticals Industries, F.Hoffmann La-Roche Ltd, Apr Applied Pharma Science Research, Acacia Pharma, Kyowa Hakko Kirin, Helsinn Healthcare, Heron Pharma, Merck & Co. Inc, Sanofi

What are the Application segmentation covered in the Cancer Supportive Care Drugs - Market report?

Ans: The Applications covered in the Cancer Supportive Care Drugs - Market report are Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, Others

What are the Type segmentation covered in the Cancer Supportive Care Drugs - Market report?

Ans: The Types covered in the Cancer Supportive Care Drugs - Market report are Granulocyte-Colony Stimulating Factors (G-CSFS), Erythropoietin-Stimulating Agents (ESAS), Antiemetics, Bisphosphonates, Opioids, Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Others

1 Market Overview
1.1 Cancer Supportive Care Drugs Product Introduction
1.2 Global Cancer Supportive Care Drugs Market Size Forecast
1.3 Cancer Supportive Care Drugs Market Trends & Drivers
1.3.1 Cancer Supportive Care Drugs Industry Trends
1.3.2 Cancer Supportive Care Drugs Market Drivers & Opportunity
1.3.3 Cancer Supportive Care Drugs Market Challenges
1.3.4 Cancer Supportive Care Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Cancer Supportive Care Drugs Players Revenue Ranking (2023)
2.2 Global Cancer Supportive Care Drugs Revenue by Company (2019-2024)
2.3 Key Companies Cancer Supportive Care Drugs Manufacturing Base Distribution and Headquarters
2.4 Key Companies Cancer Supportive Care Drugs Product Offered
2.5 Key Companies Time to Begin Mass Production of Cancer Supportive Care Drugs
2.6 Cancer Supportive Care Drugs Market Competitive Analysis
2.6.1 Cancer Supportive Care Drugs Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Cancer Supportive Care Drugs Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Supportive Care Drugs as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Granulocyte-Colony Stimulating Factors (G-CSFS)
3.1.2 Erythropoietin-Stimulating Agents (ESAS)
3.1.3 Antiemetics
3.1.4 Bisphosphonates
3.1.5 Opioids
3.1.6 Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
3.1.7 Others
3.2 Global Cancer Supportive Care Drugs Sales Value by Type
3.2.1 Global Cancer Supportive Care Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Cancer Supportive Care Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Cancer Supportive Care Drugs Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Breast Cancer
4.1.2 Lung Cancer
4.1.3 Melanoma
4.1.4 Prostate Cancer
4.1.5 Others
4.2 Global Cancer Supportive Care Drugs Sales Value by Application
4.2.1 Global Cancer Supportive Care Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Cancer Supportive Care Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Cancer Supportive Care Drugs Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Cancer Supportive Care Drugs Sales Value by Region
5.1.1 Global Cancer Supportive Care Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Cancer Supportive Care Drugs Sales Value by Region (2019-2024)
5.1.3 Global Cancer Supportive Care Drugs Sales Value by Region (2025-2030)
5.1.4 Global Cancer Supportive Care Drugs Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Cancer Supportive Care Drugs Sales Value, 2019-2030
5.2.2 North America Cancer Supportive Care Drugs Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Cancer Supportive Care Drugs Sales Value, 2019-2030
5.3.2 Europe Cancer Supportive Care Drugs Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Cancer Supportive Care Drugs Sales Value, 2019-2030
5.4.2 Asia Pacific Cancer Supportive Care Drugs Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Cancer Supportive Care Drugs Sales Value, 2019-2030
5.5.2 South America Cancer Supportive Care Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Cancer Supportive Care Drugs Sales Value, 2019-2030
5.6.2 Middle East & Africa Cancer Supportive Care Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Cancer Supportive Care Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Cancer Supportive Care Drugs Sales Value
6.3 United States
6.3.1 United States Cancer Supportive Care Drugs Sales Value, 2019-2030
6.3.2 United States Cancer Supportive Care Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Cancer Supportive Care Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Cancer Supportive Care Drugs Sales Value, 2019-2030
6.4.2 Europe Cancer Supportive Care Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Cancer Supportive Care Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Cancer Supportive Care Drugs Sales Value, 2019-2030
6.5.2 China Cancer Supportive Care Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Cancer Supportive Care Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Cancer Supportive Care Drugs Sales Value, 2019-2030
6.6.2 Japan Cancer Supportive Care Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Cancer Supportive Care Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Cancer Supportive Care Drugs Sales Value, 2019-2030
6.7.2 South Korea Cancer Supportive Care Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Cancer Supportive Care Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Cancer Supportive Care Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Cancer Supportive Care Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Cancer Supportive Care Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Cancer Supportive Care Drugs Sales Value, 2019-2030
6.9.2 India Cancer Supportive Care Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Cancer Supportive Care Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Amgen
7.1.1 Amgen Profile
7.1.2 Amgen Main Business
7.1.3 Amgen Cancer Supportive Care Drugs Products, Services and Solutions
7.1.4 Amgen Cancer Supportive Care Drugs Revenue (US$ Million) & (2019-2024)
7.1.5 Amgen Recent Developments
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Profile
7.2.2 Johnson & Johnson Main Business
7.2.3 Johnson & Johnson Cancer Supportive Care Drugs Products, Services and Solutions
7.2.4 Johnson & Johnson Cancer Supportive Care Drugs Revenue (US$ Million) & (2019-2024)
7.2.5 Johnson & Johnson Recent Developments
7.3 Novartis
7.3.1 Novartis Profile
7.3.2 Novartis Main Business
7.3.3 Novartis Cancer Supportive Care Drugs Products, Services and Solutions
7.3.4 Novartis Cancer Supportive Care Drugs Revenue (US$ Million) & (2019-2024)
7.3.5 Baxter International Recent Developments
7.4 Baxter International
7.4.1 Baxter International Profile
7.4.2 Baxter International Main Business
7.4.3 Baxter International Cancer Supportive Care Drugs Products, Services and Solutions
7.4.4 Baxter International Cancer Supportive Care Drugs Revenue (US$ Million) & (2019-2024)
7.4.5 Baxter International Recent Developments
7.5 Fagron Group
7.5.1 Fagron Group Profile
7.5.2 Fagron Group Main Business
7.5.3 Fagron Group Cancer Supportive Care Drugs Products, Services and Solutions
7.5.4 Fagron Group Cancer Supportive Care Drugs Revenue (US$ Million) & (2019-2024)
7.5.5 Fagron Group Recent Developments
7.6 Teva Pharmaceuticals Industries
7.6.1 Teva Pharmaceuticals Industries Profile
7.6.2 Teva Pharmaceuticals Industries Main Business
7.6.3 Teva Pharmaceuticals Industries Cancer Supportive Care Drugs Products, Services and Solutions
7.6.4 Teva Pharmaceuticals Industries Cancer Supportive Care Drugs Revenue (US$ Million) & (2019-2024)
7.6.5 Teva Pharmaceuticals Industries Recent Developments
7.7 F.Hoffmann La-Roche Ltd
7.7.1 F.Hoffmann La-Roche Ltd Profile
7.7.2 F.Hoffmann La-Roche Ltd Main Business
7.7.3 F.Hoffmann La-Roche Ltd Cancer Supportive Care Drugs Products, Services and Solutions
7.7.4 F.Hoffmann La-Roche Ltd Cancer Supportive Care Drugs Revenue (US$ Million) & (2019-2024)
7.7.5 F.Hoffmann La-Roche Ltd Recent Developments
7.8 Apr Applied Pharma Science Research
7.8.1 Apr Applied Pharma Science Research Profile
7.8.2 Apr Applied Pharma Science Research Main Business
7.8.3 Apr Applied Pharma Science Research Cancer Supportive Care Drugs Products, Services and Solutions
7.8.4 Apr Applied Pharma Science Research Cancer Supportive Care Drugs Revenue (US$ Million) & (2019-2024)
7.8.5 Apr Applied Pharma Science Research Recent Developments
7.9 Acacia Pharma
7.9.1 Acacia Pharma Profile
7.9.2 Acacia Pharma Main Business
7.9.3 Acacia Pharma Cancer Supportive Care Drugs Products, Services and Solutions
7.9.4 Acacia Pharma Cancer Supportive Care Drugs Revenue (US$ Million) & (2019-2024)
7.9.5 Acacia Pharma Recent Developments
7.10 Kyowa Hakko Kirin
7.10.1 Kyowa Hakko Kirin Profile
7.10.2 Kyowa Hakko Kirin Main Business
7.10.3 Kyowa Hakko Kirin Cancer Supportive Care Drugs Products, Services and Solutions
7.10.4 Kyowa Hakko Kirin Cancer Supportive Care Drugs Revenue (US$ Million) & (2019-2024)
7.10.5 Kyowa Hakko Kirin Recent Developments
7.11 Helsinn Healthcare
7.11.1 Helsinn Healthcare Profile
7.11.2 Helsinn Healthcare Main Business
7.11.3 Helsinn Healthcare Cancer Supportive Care Drugs Products, Services and Solutions
7.11.4 Helsinn Healthcare Cancer Supportive Care Drugs Revenue (US$ Million) & (2019-2024)
7.11.5 Helsinn Healthcare Recent Developments
7.12 Heron Pharma
7.12.1 Heron Pharma Profile
7.12.2 Heron Pharma Main Business
7.12.3 Heron Pharma Cancer Supportive Care Drugs Products, Services and Solutions
7.12.4 Heron Pharma Cancer Supportive Care Drugs Revenue (US$ Million) & (2019-2024)
7.12.5 Heron Pharma Recent Developments
7.13 Merck & Co. Inc
7.13.1 Merck & Co. Inc Profile
7.13.2 Merck & Co. Inc Main Business
7.13.3 Merck & Co. Inc Cancer Supportive Care Drugs Products, Services and Solutions
7.13.4 Merck & Co. Inc Cancer Supportive Care Drugs Revenue (US$ Million) & (2019-2024)
7.13.5 Merck & Co. Inc Recent Developments
7.14 Sanofi
7.14.1 Sanofi Profile
7.14.2 Sanofi Main Business
7.14.3 Sanofi Cancer Supportive Care Drugs Products, Services and Solutions
7.14.4 Sanofi Cancer Supportive Care Drugs Revenue (US$ Million) & (2019-2024)
7.14.5 Sanofi Recent Developments
8 Industry Chain Analysis
8.1 Cancer Supportive Care Drugs Industrial Chain
8.2 Cancer Supportive Care Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Cancer Supportive Care Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Cancer Supportive Care Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
    Table 1. Cancer Supportive Care Drugs Market Trends
    Table 2. Cancer Supportive Care Drugs Market Drivers & Opportunity
    Table 3. Cancer Supportive Care Drugs Market Challenges
    Table 4. Cancer Supportive Care Drugs Market Restraints
    Table 5. Global Cancer Supportive Care Drugs Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Cancer Supportive Care Drugs Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Cancer Supportive Care Drugs Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Cancer Supportive Care Drugs Product Type
    Table 9. Key Companies Time to Begin Mass Production of Cancer Supportive Care Drugs
    Table 10. Global Cancer Supportive Care Drugs Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Supportive Care Drugs as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Cancer Supportive Care Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Cancer Supportive Care Drugs Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Cancer Supportive Care Drugs Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Cancer Supportive Care Drugs Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Cancer Supportive Care Drugs Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Cancer Supportive Care Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Cancer Supportive Care Drugs Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Cancer Supportive Care Drugs Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Cancer Supportive Care Drugs Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Cancer Supportive Care Drugs Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Cancer Supportive Care Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Cancer Supportive Care Drugs Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Cancer Supportive Care Drugs Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Cancer Supportive Care Drugs Sales Value by Region (2019-2024) & (%)
    Table 27. Global Cancer Supportive Care Drugs Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Cancer Supportive Care Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Cancer Supportive Care Drugs Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Cancer Supportive Care Drugs Sales Value, (2025-2030) & (US$ Million)
    Table 31. Amgen Basic Information List
    Table 32. Amgen Description and Business Overview
    Table 33. Amgen Cancer Supportive Care Drugs Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Cancer Supportive Care Drugs Business of Amgen (2019-2024)
    Table 35. Amgen Recent Developments
    Table 36. Johnson & Johnson Basic Information List
    Table 37. Johnson & Johnson Description and Business Overview
    Table 38. Johnson & Johnson Cancer Supportive Care Drugs Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Cancer Supportive Care Drugs Business of Johnson & Johnson (2019-2024)
    Table 40. Johnson & Johnson Recent Developments
    Table 41. Novartis Basic Information List
    Table 42. Novartis Description and Business Overview
    Table 43. Novartis Cancer Supportive Care Drugs Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Cancer Supportive Care Drugs Business of Novartis (2019-2024)
    Table 45. Novartis Recent Developments
    Table 46. Baxter International Basic Information List
    Table 47. Baxter International Description and Business Overview
    Table 48. Baxter International Cancer Supportive Care Drugs Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Cancer Supportive Care Drugs Business of Baxter International (2019-2024)
    Table 50. Baxter International Recent Developments
    Table 51. Fagron Group Basic Information List
    Table 52. Fagron Group Description and Business Overview
    Table 53. Fagron Group Cancer Supportive Care Drugs Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Cancer Supportive Care Drugs Business of Fagron Group (2019-2024)
    Table 55. Fagron Group Recent Developments
    Table 56. Teva Pharmaceuticals Industries Basic Information List
    Table 57. Teva Pharmaceuticals Industries Description and Business Overview
    Table 58. Teva Pharmaceuticals Industries Cancer Supportive Care Drugs Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Cancer Supportive Care Drugs Business of Teva Pharmaceuticals Industries (2019-2024)
    Table 60. Teva Pharmaceuticals Industries Recent Developments
    Table 61. F.Hoffmann La-Roche Ltd Basic Information List
    Table 62. F.Hoffmann La-Roche Ltd Description and Business Overview
    Table 63. F.Hoffmann La-Roche Ltd Cancer Supportive Care Drugs Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Cancer Supportive Care Drugs Business of F.Hoffmann La-Roche Ltd (2019-2024)
    Table 65. F.Hoffmann La-Roche Ltd Recent Developments
    Table 66. Apr Applied Pharma Science Research Basic Information List
    Table 67. Apr Applied Pharma Science Research Description and Business Overview
    Table 68. Apr Applied Pharma Science Research Cancer Supportive Care Drugs Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Cancer Supportive Care Drugs Business of Apr Applied Pharma Science Research (2019-2024)
    Table 70. Apr Applied Pharma Science Research Recent Developments
    Table 71. Acacia Pharma Basic Information List
    Table 72. Acacia Pharma Description and Business Overview
    Table 73. Acacia Pharma Cancer Supportive Care Drugs Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Cancer Supportive Care Drugs Business of Acacia Pharma (2019-2024)
    Table 75. Acacia Pharma Recent Developments
    Table 76. Kyowa Hakko Kirin Basic Information List
    Table 77. Kyowa Hakko Kirin Description and Business Overview
    Table 78. Kyowa Hakko Kirin Cancer Supportive Care Drugs Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Cancer Supportive Care Drugs Business of Kyowa Hakko Kirin (2019-2024)
    Table 80. Kyowa Hakko Kirin Recent Developments
    Table 81. Helsinn Healthcare Basic Information List
    Table 82. Helsinn Healthcare Description and Business Overview
    Table 83. Helsinn Healthcare Cancer Supportive Care Drugs Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Cancer Supportive Care Drugs Business of Helsinn Healthcare (2019-2024)
    Table 85. Helsinn Healthcare Recent Developments
    Table 86. Heron Pharma Basic Information List
    Table 87. Heron Pharma Description and Business Overview
    Table 88. Heron Pharma Cancer Supportive Care Drugs Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Cancer Supportive Care Drugs Business of Heron Pharma (2019-2024)
    Table 90. Heron Pharma Recent Developments
    Table 91. Merck & Co. Inc Basic Information List
    Table 92. Merck & Co. Inc Description and Business Overview
    Table 93. Merck & Co. Inc Cancer Supportive Care Drugs Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Cancer Supportive Care Drugs Business of Merck & Co. Inc (2019-2024)
    Table 95. Merck & Co. Inc Recent Developments
    Table 96. Sanofi Basic Information List
    Table 97. Sanofi Description and Business Overview
    Table 98. Sanofi Cancer Supportive Care Drugs Products, Services and Solutions
    Table 99. Revenue (US$ Million) in Cancer Supportive Care Drugs Business of Sanofi (2019-2024)
    Table 100. Sanofi Recent Developments
    Table 101. Key Raw Materials Lists
    Table 102. Raw Materials Key Suppliers Lists
    Table 103. Cancer Supportive Care Drugs Downstream Customers
    Table 104. Cancer Supportive Care Drugs Distributors List
    Table 105. Research Programs/Design for This Report
    Table 106. Key Data Information from Secondary Sources
    Table 107. Key Data Information from Primary Sources
    Table 108. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Cancer Supportive Care Drugs Product Picture
    Figure 2. Global Cancer Supportive Care Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Cancer Supportive Care Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 4. Cancer Supportive Care Drugs Report Years Considered
    Figure 5. Global Cancer Supportive Care Drugs Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Cancer Supportive Care Drugs Revenue in 2023
    Figure 7. Cancer Supportive Care Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Granulocyte-Colony Stimulating Factors (G-CSFS) Picture
    Figure 9. Erythropoietin-Stimulating Agents (ESAS) Picture
    Figure 10. Antiemetics Picture
    Figure 11. Bisphosphonates Picture
    Figure 12. Opioids Picture
    Figure 13. Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) Picture
    Figure 14. Others Picture
    Figure 15. Global Cancer Supportive Care Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 16. Global Cancer Supportive Care Drugs Sales Value Market Share by Type, 2023 & 2030
    Figure 17. Product Picture of Breast Cancer
    Figure 18. Product Picture of Lung Cancer
    Figure 19. Product Picture of Melanoma
    Figure 20. Product Picture of Prostate Cancer
    Figure 21. Product Picture of Others
    Figure 22. Global Cancer Supportive Care Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 23. Global Cancer Supportive Care Drugs Sales Value Market Share by Application, 2023 & 2030
    Figure 24. North America Cancer Supportive Care Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 25. North America Cancer Supportive Care Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 26. Europe Cancer Supportive Care Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 27. Europe Cancer Supportive Care Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 28. Asia Pacific Cancer Supportive Care Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 29. Asia Pacific Cancer Supportive Care Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 30. South America Cancer Supportive Care Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 31. South America Cancer Supportive Care Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 32. Middle East & Africa Cancer Supportive Care Drugs Sales Value (2019-2030) & (US$ Million)
    Figure 33. Middle East & Africa Cancer Supportive Care Drugs Sales Value by Country (%), 2023 VS 2030
    Figure 34. Key Countries/Regions Cancer Supportive Care Drugs Sales Value (%), (2019-2030)
    Figure 35. United States Cancer Supportive Care Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 36. United States Cancer Supportive Care Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 37. United States Cancer Supportive Care Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 38. Europe Cancer Supportive Care Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 39. Europe Cancer Supportive Care Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 40. Europe Cancer Supportive Care Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 41. China Cancer Supportive Care Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 42. China Cancer Supportive Care Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 43. China Cancer Supportive Care Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 44. Japan Cancer Supportive Care Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 45. Japan Cancer Supportive Care Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 46. Japan Cancer Supportive Care Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 47. South Korea Cancer Supportive Care Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 48. South Korea Cancer Supportive Care Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 49. South Korea Cancer Supportive Care Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 50. Southeast Asia Cancer Supportive Care Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 51. Southeast Asia Cancer Supportive Care Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 52. Southeast Asia Cancer Supportive Care Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 53. India Cancer Supportive Care Drugs Sales Value, (2019-2030) & (US$ Million)
    Figure 54. India Cancer Supportive Care Drugs Sales Value by Type (%), 2023 VS 2030
    Figure 55. India Cancer Supportive Care Drugs Sales Value by Application (%), 2023 VS 2030
    Figure 56. Cancer Supportive Care Drugs Industrial Chain
    Figure 57. Cancer Supportive Care Drugs Manufacturing Cost Structure
    Figure 58. Channels of Distribution (Direct Sales, and Distribution)
    Figure 59. Bottom-up and Top-down Approaches for This Report
    Figure 60. Data Triangulation
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS